Global Human Recombinant Insulin Market Is Estimated To Witness High Growth Owing To Increasing Demand for Diabetes Management

1
Global Human Recombinant Insulin Market Is
Estimated To Witness High Growth Owing To
Increasing Demand for Diabetes Management
The global Human Recombinant Insulin Market is
estimated to be valued at US 36,134.5 million in
2022 and is expected to exhibit a CAGR of 7.3
over the forecast period 2022-2030, as
highlighted in a new report published by
Coherent Market Insights. This growth can be
attributed to the increasing demand for diabetes
management and the advantages associated with
human recombinant insulin products. A) Market
Overview Recombinant insulin is a type of
insulin that is produced by genetically modifying
bacteria or yeast cells. These products are
widely used in the treatment of diabetes,
particularly type 1 diabetes. The key advantage
of human recombinant insulin is its similarity to
natural insulin, which allows for better
absorption and utilization in the body. These
products have revolutionized diabetes management
and have greatly improved the quality of life for
patients. The increasing prevalence of diabetes
and the need for effective treatment options are
driving the growth of the global human
recombinant insulin market. B) Market Key
Trends One key trend in the human recombinant
insulin market is the growing adoption of insulin
analogs. Insulin analogs are modified versions
of human recombinant insulin that have been
designed to mimic the natural insulin production
in the body more closely. These analogs offer
advantages such as faster onset of action,
longer duration of action, and reduced risk of
hypoglycemia. This has led to increased adoption
among healthcare professionals and patients,
driving market growth. For example, Novo
Nordisk, one of the key players in the market,
offers a range of insulin analogs including
long-acting and rapid-acting analogs. C) PEST
Analysis
2
Political The government's initiatives and
policies to promote diabetes management and
improve access to healthcare services play a
crucial role in the growth of the human
recombinant insulin market. Economic The
economic factors such as disposable income and
healthcare expenditure influence the
affordability and accessibility of human
recombinant insulin products. Social The
increasing prevalence of diabetes and the growing
awareness about the importance of diabetes
management contribute to market growth.
Technological Advancements in technology have
led to the development of more advanced insulin
delivery devices, such as insulin pens and
insulin pumps, which enhance the convenience and
effectiveness of insulin therapy. D) Key
Takeaways - The global Human Recombinant
Insulin Market is expected to witness high
growth, exhibiting a CAGR of 7.3 over the
forecast period, due to increasing demand for
diabetes management. - North America is expected
to be the fastest-growing and dominating region
in the market, driven by a high prevalence of
diabetes and favorable healthcare policies. -
Key players operating in the global human
recombinant insulin market include Novo Nordisk
A/S, Eli Lilly and Company, Sanofi S.A., Julphar
Gulf Pharmaceutical Industries, Biocon Limited,
Bioton S.A., Gan Lee Pharmaceuticals, Ltd.,
Zhuhai United Laboratories Co., Ltd., Wanbang
Biopharmaceuticals Co., Ltd., and Dongbao
Enterprise Group Co., Ltd. In conclusion, the
global human recombinant insulin market is poised
for substantial growth due to the increasing
demand for diabetes management. The adoption of
insulin analogs and advancements in technology
are driving market growth. North America is
expected to be the fastest- growing region, and
key players in the market are focusing on
innovation and strategic collaborations to gain
a competitive edge.